Acute Pancreatitis Market Size Global Gathering and Future Outlook 2020 to 2027

 

Market Research Future (MRFR) has reported an expected CAGR of 3.5% for the global acute pancreatitis market during the forecast period of 2017 to 2023. The increasing occurrence of this severely painful condition is expected to be a key driver of growth for the market.

Although there have been advancements in the development of effective treatment options for the disease, there is still a significant mortality rate of 10% which has fueled the demand for better diagnostic and treatment options. Developed and developing economies have been found to have a higher occurrence of acute pancreatitis due to the prevalence of heavy alcohol consumption and unhealthy lifestyles which cause gallstones. Urbanization, growing healthcare sector and growing consumption of alcohol are expected to drive market growth during the forecast period.

Difficulty in the diagnosis of the disease due to the relative inaccessibility of the organ is a crucial challenge for the market. However, the demand for appropriately effective diagnostic and treatment options is expected to prompt more in-depth research and development of the same, thus facilitating growth and opening new avenues for opportunities in the next few years.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1565

Market Segmentation

Segmentation of the global acute pancreatitis market has been performed by types of testing, types of treatment, types of therapy and region.

By types of testing, the market has been segmented to include Magnetic resonance cholangiopancreatography (MRCP), Computerized tomography (CT), transabdominal ultrasound, Endoscopic ultrasound (EUS), and others.

By types of treatment, the market has been divided into treatment of underlying issues, nutritional support, fluids, Endoscopic Retrograde Cholangiopancreatography (ERCP) and others.

By types of therapy, the market has been segmented to include massage therapy, therapeutic touch, acupuncture, and others.

By region, the global market has been divided into North America, Europe, the Asia-Pacific and the Middle East and Africa.

Regional Analysis

North America, with its dominating share, is expected to fuel growth for the market due to the growing incidence of acute pancreatitis and high demand for effective treatment options for the same. The region boasts a strong healthcare sector with growing expenditure on research for the development of appropriate treatment measures, thus fostering market growth.

Europe closely follows with the second most significant market share. This can be attributed to the widespread occurrence of the disease in the region. Many developed countries of the region are seeing growing diagnoses of the condition due to gallstones, while the developing economies in the region with a reputation for high alcohol consumption are responsible for increased incidences of acute pancreatitis in the region.

The Asia Pacific has a vast patient population which has rising disposable incomes in its emerging economies thus fueling demand for modern treatment options. Moreover, there is growing investment in healthcare in this region which facilitates growth further.

The Middle East and Africa are expected to show limited growth, with the low development of the medical sector in the underdeveloped countries of Africa. Growth in the region is likely to be witnessed in the Middle East and North African region where there is sufficient development of the healthcare sector.

Key Players

Competitive analysis in MRFR's report on the global acute pancreatitis market includes prominent market leaders such as Abbott Laboratories, Sun BioPharma Inc., McNeil Consumer Healthcare and others. Additionally, the report contains an analysis of contributions made by universities to the market and its growth including universities such as University Medicine Greifswald, and Radboud University among others.

Latest Industry News

Akcea Therapeutics has announced FDA approval of Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), which is often accompanied by fatal acute pancreatitis. The new drug is expected to reduce the risk of acute pancre

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565  

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com